Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 06, 2026 07:00 ET | Source: WuXi AppTec

Integrated Development Helps Targeted Protein Degraders Reach the Clinic

WuXi AppTec shows how integrated CRDMO platforms help protein degrader programs reach the clinic by connecting chemistry, biology, and CMC early.
June 08, 2026 07:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics announces FDA clearance of IND application for AMX-883, its lead Targeted Glue™ degrader for acute myeloid leukaemia

Amphista to initiate its first clinical trial for AMX-883, a potent, orally bioavailable DCAF16-dependent degrader of BRD9, for acute myeloid leukaemia (AML) in H2 2026The Phase 1 monotherapy...